Meeting brief

US market entry — board working session, Northwind Workforce

Company: Northwind Workforce; northwind-workforce.example
Primary attendee: Yusuf Aboagye; Chief Executive Officer
Objective: Reframe the US entry conversation into three sequenced decisions and position the firm to lead the 60-day options paper before any US hiring.

Also attending

Helen Dalrymple · Chair
Ravi Sundaram · CFO
Marie Chen · NED · former CRO, a leading EMEA HR-tech platform

Executive summary

Northwind is a £42M-ARR PE-backed UK SaaS business with strong unit economics, a board now actively debating US entry, and a new CRO already building informal pipeline in New York. The conversation is being framed as 'when' rather than 'how' — which is where most expansion failures begin. The outcome to drive: board agreement to a 60-day options paper led by the firm before any US hiring is committed.

Key talking points

For the lift up

01Reframe 'when' into 'how' — sequenced decisions, not a single Go/No-Go
02Anchor on Marie Chen's US scaling experience early in the room
03Position a 60-day options paper as the gating step before US hiring
04Surface Acme's reset exit clock as the real commercial pressure
05Acknowledge the CRO's NY pipeline without legitimising it as strategy

Company context

Workforce planning and scenario modelling SaaS for HR and finance teams in 1,000–10,000-employee organisations. UK and Benelux home markets. NRR 118%, gross margin 78%, Rule of 40 ~52. Acme Capital led a £30M Series C in 2023 and took a small secondary in the same round — patient capital, but a clear expectation of a category-leader outcome that only credibly works with a US footprint.

Attendee profile

Yusuf Aboagye — CEO: Second-time founder; first company sold to a major European enterprise software acquirer in 2018. Decisive, biased to speed, has limited patience for advisors who present options without a recommendation. Has signalled US ambition publicly, which is now shaping internal expectations faster than the board is comfortable with.

Helen Dalrymple — Chair: Cautious sponsor; will value a structured decision frame over a fast answer.

Ravi Sundaram — CFO: Owns the capital question; will push back on anything that pre-commits the funding path.

Marie Chen — NED: Has lived US scaling at a leading EMEA HR-tech platform; the natural ally for a disciplined approach if engaged early, and the natural blocker if worked around.

Group dynamic: Yusuf is decision-maker, Helen is sponsor, Ravi is economic buyer on capital, Marie is the swing vote.

Strategic signals

New CRO hired from US competitor in March
Summarybuilding NY pipeline informally, no board mandate yet.
Two UK enterprise deals lost in Q1 to US-headquartered HRIS incumbent
Summarycompetitive threat is already in the home market.
Acme Capital's secondary in last round
Summarysignals patience, but quietly resets the exit clock to ~24 months.
Marie Chen joined the board in December specifically for US scaling experience
Summaryshe will frame the room.
All-hands references to 'category leader' ambition
Summaryinternal expectations running ahead of the board.

Likely priorities

Establishing credible US presence before the next funding event (~12–18 months out).
Avoiding the classic UK-to-US scale-up failure pattern — over-hire, under-localise, burn 18 months.
Holding internal momentum after publicly signalling the US ambition.
Aligning the board on a single defensible plan, not a compromise of preferences.

Conversation angles

Reframe from 'when do we enter' to 'what is the smallest experiment that would falsify the thesis'.
Use the Q1 UK deal losses to a US incumbent as the entry point — the threat is already domestic.
Bring Marie into the framing in the first ten minutes; her experience is the firm's air-cover.
One-page comparison of three SaaS companies that entered the US well and three that didn't — patterns, not anecdotes.

Discovery questions

01Twenty-four months from now, what would have to be true for the board to call US entry a success — and what would you have wished you'd done differently?
02How much of the CRO's New York pipeline is genuine signal versus enthusiasm, and how would we test the difference in 30 days?
03What's your honest appetite for the operating distraction of a US acquisition versus a build, given where the UK business is in its growth curve?
04How is Acme Capital thinking about funding the entry — bridge, primary in 18 months, or strategic?
05What's the smallest commitment you could make in the next 90 days that would meaningfully de-risk the bigger decision?

Opportunities

60-day US market entry options paper — partner-led — £180–240k framed for the next board.
Pricing and packaging diagnostic against the US incumbent that won the Q1 UK deals — £60–90k.
Bolt-on target screening (£10–25M revenue range) — initial outreach, no banker mandate yet.
Board governance workshop on overseeing US entry — annuity into the next 18 months.

Risks & sensitivities

Yusuf has signalled US entry publicly — framing this as 'should you enter at all' burns credibility.
The new CRO is already acting on a thesis; pausing her work needs handling, not a memo.
Marie may read firm involvement as encroaching on her board mandate — engage her, don't route around her.
Acme Capital will want optionality on capital — avoid recommending anything that locks the funding path.

Suggested next steps

01Issue scoping note for the 60-day options paper — by Friday — engagement partner.
021:1 with Marie Chen ahead of the next board to align on framing — within 10 days — partner.
03Quiet desk-screen of three US bolt-on candidates — within 3 weeks — corporate finance lead.

Suggested follow-up email

Subject

Northwind US entry — proposed next step for the board

Hi Yusuf,

A strong working session today. To capture where we landed:

We agreed the right framing for the next board is three sequenced decisions — beachhead vs. national, channel vs. direct, build vs. acquire — rather than a single 'go US' decision. We'd propose to lead a 60-day options paper into the [board date], working with Ravi on the financial frame and with your CRO on validating the early NY pipeline signals.

In parallel, we'll quietly desk-screen a short list of US bolt-on targets so the board has a real option, not a hypothetical one. I'll circulate a scoping note by Friday for you and Helen to react to.
Best,
[Your name]